<DOC>
	<DOCNO>NCT00001570</DOCNO>
	<brief_summary>Bolus PSC 833 administer Day 1 simultaneously initiation 24 hour continuous infusion PSC 833 , follow another continuous infusion last additional 6 day . To ensure safety 7 day infusion PSC 833 , one patient treat 5 day second 6 day , first cohort enrol . Vinblastine administer escalate dos day 2-5 . At least 3 patient enter dose level . The MTD define dose immediately 2 patient experience dose limit toxicity . Treatment continue every 28 day .</brief_summary>
	<brief_title>A Phase I Study Continuous Intravenous Infusion PSC 833 Vinblastine Patients With Metastatic Renal Cancer</brief_title>
	<detailed_description>The Phase I clinical trial combination 120-hour continuous intravenous infusion vinblastine oral PSC 833 show activity patient advanced malignancy , particularly renal cell cancer . The MTD vinblastine combination oral drink solution PSC 833 determine 0.9 mg/m2/day five day 12.5 mg/kg po q 12 hour eight day , respectively . For soft gel capsule formulation , MTD determine 0.6 mg/m2/day vinblastine five day 4 mg/kg po q 6 hour PSC 833 eight day . Ataxia dose limit toxicity . Of 46 patient , two complete remission one partial remission see among 29 patient renal cell carcinoma . In Phase I study , patient advance renal carcinoma treat escalate dos vinblastine give 72 hour infusion , start approximately 40 % total standard dose . A short infusion schedule vinblastine choose since evidence cytotoxic combination PSC 833 increase AUC decrease plasma clearance chemotherapeutic agent approximately twofold . Cytochrome P 450 3A CYP3A , major cytochrome enzyme metabolism vinblastine PSC 833 , measure first fourth cycle vivo test use single intravenous dose midazolam , short-acting benzodiazepine . Vinblastine PSC 833 pharmacokinetics perform time . For patient accessible lesion , tumor biopsy request .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove renal cancer clear cell component : Measurable evaluable disease ; No brain metastasis ; No grade 2 great peripheral neuropathy neurologic toxicity symptom . PRIOR/CONCURRENT THERAPY : Biologic Therapy : Not specify . Chemotherapy : No prior concurrent hypersensitivity PSC 833 cyclosporine A. Endocrine Therapy : Not specify . Radiotherapy : No prior radiation therapy within 4 week study . Surgery : No major surgery within 4 week study . Other : No concurrent treatment interfere cyclosporine blood concentration . PATIENT CHARACTERISTICS : Age : 18 . Performance Status : ECOG 02 . Life Expectancy : At least 16 week . Hematopoietic : ANC great equal 1500/mm ( 3 ) ; Platelet count great equal 100,000/mm ( 3 ) . Hepatic : Bilirubin great 1.5 x normal ; AST great 2.5 x normal . Renal : Creatinine great 2.0 mg/dL OR ; Creatinine clearance great equal 50 mL/min . Cardiovascular : No concurrent angina myocardial infarction appropriately treat . Other : Not pregnant nursing . Effective contraceptive require fertile patient . Patients history curatively treat basal cell squamous cell carcinoma eligible . No HIV seropositivity . No chronic hepatitis cirrhosis . Patients concurrent reversible condition diabetes , hypercalcemia , hyperuricemia , hyperviscosity , infection , renal disease , spinal cord compression eligible appropriate therapy . Patients must give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>Cytochrome P 450</keyword>
	<keyword>Multi-Drug Resistance</keyword>
	<keyword>P-Glycoprotein</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>